InCarda Therapeutics, Inc

04/06/2022

InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective

April 6, 2022 In News InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective The original article titled “Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution fo...

04/06/2022

Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm

Harry J.G.M. Crijns, Arif Elvan, Nadea Al-Windy, Ype S. Tuininga, Erik Badings, Ismail Aksoy, Isabelle C. Van Gelder, Prashanti Madhavapeddi, A. John Camm, Peter R. Kowey, Jeremy N. Ruskin, Luiz Belardinelli and the INSTANT Investigators*
Originally published 24 Feb 2022 https://doi.org/10.1161/CIRCEP.121.010204Circulation: Arrhythmia and Electrophysiology. 2022;15

02/11/2021

InCarda CEO, Grace Colon, was interviewed for this brief and informative piece on Atrial Fibrillation by Julie Stewart in the February 2021 edition of Men’s Health.💜

It's all about rhythm.

01/19/2021

Excited to announce enrollment of our first US patient in for our Phase 2 INSTANT study for . We are looking forward to advancing our lead program into P3 later this year!

January 19, 2021 In News, Press Releases InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of A...

11/19/2020

BIG NEWS! Tune in to our media briefing via Facebook Live tomorrow at 8:00 am PT/11:00 am ET.

We'll discuss the launch of the first of its kind California Boardroom Equity Scorecard & Tracker—with additional remarks from Senator María Elena Durazo (CA Senate District 24) Chair, California Latino Caucus, Debra Sandler, LCDA Member and Board Member of Dollar General, Archer Daniels Midland and Gannett Co., and Grace Colon, LCDA Member and President & CEO InCarda Therapeutics, Inc., Board Member of CareDx, Inc. and Proterix Bio.

>> https://fb.me/e/1QkqJH81D

11/13/2020

Exciting news today...We have released P2 data from our INSTANT study for our lead product in atrial fibrillation. It is a big step to show that rapid, non-invasive conversion of AF episodes is possible!

November 13, 2020 In Press Releases InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020 Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to N...

11/10/2020

Check out InCarda at AHA on Friday!
InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020).

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of the company’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF). The poster presentation is entitled "An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner” and is included in the AHA session entitled “Anti Arrhythmic Drug Considerations in 2020.”

This year’s event may be virtual, but there will be the same amount of networking opportunities available as our in-person gatherings!

11/10/2020

Check us out at AHA on Friday.
InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020).
On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of the company’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF). The poster presentation is entitled "An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner” and is included in the AHA session entitled “Anti Arrhythmic Drug Considerations in 2020.”

This year’s event may be virtual, but there will be the same amount of networking opportunities available as our in-person gatherings!

02/06/2020

Our CEO Grace Colón spoke with Erik Clausen of CG Life at last month.

https://informaconnect.com/biotech-showcase/ InCarda Therapeutics CEO Grace Colón, PhD, meets with CG Life Managing Partner Erik Clausen at Biotech Showcase ...

08/07/2019

Digital health is evolving rapidly to greatly change how we treat diseases for the better. Check out our CEO, Grace Colon discuss digital health at MassBio!

MassBio represents 1,200+ life sciences companies and organizations involved with the industry. We are available to comment and provide background on public policy, economic development, education, workforce development and other key life sciences issues.